Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

DYN holding history

Dyne Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

DYN overviewAll 13F holders of DYNFull Q2 2026 holdings

Shares (Q2 2026)
443,284
Value
$9.85M
% of portfolio
<0.1%
Quarters held
21
Since Q1 2021
Holdings of DYN by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026443,284$9.85M<0.1%+62,723+16.5%AddedHolders
Q1 2026380,561$6.90M<0.1%−417−0.1%ReducedHolders
Q4 2025380,978$7.45M<0.1%+31,590+9.0%AddedHolders
Q3 2025349,388$4.42M<0.1%+227,596+186.9%AddedHolders
Q2 2025121,792$1.16M<0.1%−235,962−66.0%ReducedHolders
Q1 2025357,754$3.74M<0.1%−182,358−33.8%ReducedHolders
Q4 2024540,112$12.7M<0.1%−85,607−13.7%ReducedHolders
Q3 2024625,719$22.5M<0.1%+381,790+156.5%AddedHolders
Q2 2024243,929$8.61M<0.1%+10,602+4.5%AddedHolders
Q1 2024233,327$6.62M<0.1%+109,277+88.1%AddedHolders
Q4 2023124,050$1.65M<0.1%+69,892+129.1%AddedHolders
Q3 202354,158$485.3K<0.1%+31,589+140.0%AddedHolders
Q2 202322,569$253.9K<0.1%+21,120+1,457.6%AddedHolders
Q1 20231,449$16.7K<0.1%−8,127−84.9%ReducedHolders
Q4 20229,576$111.0K<0.1%+8,530+815.5%AddedHolders
Q3 20221,046$13.0K<0.1%+16+1.6%AddedHolders
Q2 20221,030$7.00K<0.1%−9,142−89.9%ReducedHolders
Q1 202210,172$98.0K<0.1%+9,760+2,368.9%AddedHolders
Q4 2021412$5.00K<0.1%+387+1,548.0%AddedHolders
Q3 202125$00.0%+25NewHolders
Q2 20210$00.0%−3,278−100.0%Sold outHolders
Q1 20213,278$51.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.